New research indicates that users of popular weight-loss medications known as GLP-1 receptor agonists, including Ozempic and Wegovy, may face an increased risk of divorce, according to experts analyzing emerging data patterns.

The findings suggest that patients using these medications could experience divorce rates roughly double that of the general population, mirroring trends previously documented among individuals who undergo bariatric surgery procedures.

GLP-1 receptor agonists have gained widespread attention and usage as treatments for diabetes and weight management, with millions of Americans now prescribed these medications. The drugs work by mimicking hormones that regulate blood sugar and slow digestion, often leading to significant weight loss.

Experts note that the potential relationship between these medications and marital outcomes represents an area requiring further investigation, as the psychological and social effects of rapid weight loss and lifestyle changes may impact personal relationships.

The research builds on existing studies of bariatric surgery patients, where similar increases in divorce rates have been documented following significant weight loss. Researchers suggest that major physical transformations can sometimes strain existing relationships or alter personal dynamics between spouses.

While the medications continue to be prescribed widely for their primary medical benefits, healthcare providers may need to consider counseling patients about potential social and relationship impacts alongside the known medical effects of treatment.